CUE
NASDAQ · Biotechnology
Cue Biopharma Inc
$0.32
+0.00 (+1.27%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 17.29M | 17.52M | 19.24M |
| Net Income | -1,405,095 | -1,532,650 | -1,824,826 |
| EPS | — | — | — |
| Profit Margin | -8.1% | -8.8% | -9.5% |
| Rev Growth | -1.5% | +0.6% | +3.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 11.29M | 12.69M | 12.70M |
| Total Equity | 9.33M | 8.33M | 9.35M |
| D/E Ratio | 1.21 | 1.52 | 1.36 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -1,931,193 | -1,913,244 | -2,419,019 |
| Free Cash Flow | -1,435,133 | -1,533,941 | -1,392,757 |